BeOne Medicines AG
BeOne Medicines's GHG Emissions Data Preview
In 2024, BeOne Medicines completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
BeOne Medicines has also provided a category-level breakdown for 11 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Unspecified Calculation Method | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  b | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
aVerified Sources Behind BeOne Medicines’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore BeOne Medicines’s data sources below and access millions more through our Disclosure Search.
Insights into BeOne Medicines's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of BeOne Medicines amounted to 84,642 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of BeOne Medicines increased by 7.21%, suggesting that the company faced challenges in reducing its emissions from its core operations. a
BeOne Medicines's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are BeOne Medicines's Scope 1 emissions?
In 2024, the total Scope 1 emissions of BeOne Medicines were 3,547 metric tons of CO₂ equivalent (tCO₂e). a
Has BeOne Medicines reduced its Scope 1 emissions over time?
Since 2018, BeOne Medicines's Scope 1 emissions have increased by 562.99%, reflecting a rising long-term trend in Scope 1 emissions over time. a c
Compared to the previous year (2023), BeOne Medicines's Scope 1 emissions increased by 44.07%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a
What are BeOne Medicines's Scope 2 emissions?
In 2024, BeOne Medicines reported Scope 2 greenhouse gas (GHG) emissions of 89,591 tCO₂e using the market-based method and 81,095 tCO₂e using the location-based method. a
Has BeOne Medicines reduced its Scope 2 emissions over time?
Compared to the previous year (2023), BeOne Medicines's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that BeOne Medicines 's emissions have plateaued with no significant change in its energy consumption footprint. a
What methodology does BeOne Medicines use for Scope 2 reporting?
In 2024, BeOne Medicines reported its Scope 2 emissions using the market-based method and using the location-based method. a
BeOne Medicines's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
- Total Scope 2 Market-Based
- Total Scope 2 (Unspecified Calculation Method)
Insights into BeOne Medicines's Value Chain Emissions
In 2024, BeOne Medicines reported 662,689.008 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a
The 2024 disclosure of BeOne Medicines includes a breakdown across 11 of the 15 Scope 3 categories defined by the GHG Protocol, up from 10 in 2023, reflecting improved emissions accounting practices and greater transparency across the company's value chain a
BeOne Medicines's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are BeOne Medicines's Scope 3 emissions?
In 2024, BeOne Medicines reported total Scope 3 emissions of 662,689.008 metric tons of CO₂ equivalent (tCO₂e). a
Approximately 99.9% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0.1% came from downstream activities like product use, distribution, and end-of-life treatment. a
Compared to the previous year (2023), BeOne Medicines's Scope 3 emissions increased by 38.94%, suggesting that the company faced challenges in reducing emissions across its value chain. a b
What categories of Scope 3 emissions does BeOne Medicines disclose?
In 2024, BeOne Medicines reported emissions for 11 out of the 15 Scope 3 categories defined by the GHG Protocol. a
This reflects a high level of granularity and transparency in the company's emissions reporting.
What are the main sources of BeOne Medicines's Scope 3 emissions?
In 2024, the largest contributors to BeOne Medicines's Scope 3 emissions were: a
- Purchased Goods and Services (Cat. 1): 505,006 tCO₂e (76.21%)
- Capital Goods (Cat. 2): 81,940 tCO₂e (12.36%)
- Fuel- and Energy-Related Services (Cat. 3): 24,771 tCO₂e (3.74%)
BeOne Medicines's Scope 3 Emissions by Categories
Insights into BeOne Medicines’s GHG Emissions Intensity Compared to Industry Peers
In 2024, BeOne Medicines reported Scope 1 greenhouse gas (GHG) emissions of 3,547 tCO₂e and total revenues of USD 27,369 millions. This translates into an emissions intensity of 0.13 tCO₂e per millions USD. a
BeOne Medicines's Scope 1 Emissions Intensity Compared to Peers
How does BeOne Medicines's GHG emissions intensity compare to its peers?
In 2024, BeOne Medicines reported a Scope 1 emissions intensity of 0.13 tCO₂e per millions USD. Compared to the peer group median of 4.41 , this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors. a
Where does BeOne Medicines rank on GHG emissions intensity within its industry?
In 2024, BeOne Medicines ranked 2 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a
This places BeOne Medicines among the top performers, with one of the lowest emissions intensities relative to peers. a
Insights into BeOne Medicines's Total Carbon Footprint
In 2024, BeOne Medicines reported a total carbon footprint of 747,331.008 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 34.43% increase compared to 2023, suggesting a rise in emissions across its operations or value chain. a b
The largest contributor to BeOne Medicines's total carbon footprint was Scope 3 emissions, accounting for 88.67% of the company's total carbon footprint, followed by Scope 2 emissions at 10.85%. a